Remus Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →See revenue, profit and what management said. You are viewing Q4 FY26.
RP

Remus Pharmaceuticals Ltd

Q4 FY26

Remus Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

What the Q4 FY26 call signalled

3 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising
Price₹1,002
Market cap₹1.2K Cr
P/E31.9

The short version

Future Growth Expectations for Remus Pharmaceuticals: - Revenue Growth: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets. Remus Pharmaceuticals expects significant growth in both B2C and B2B segments in FY 2027.

From Remus Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth
Future Growth Expectations for Remus Pharmaceuticals: - **Revenue Growth**: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets. - **B2C Segment**: Expected to grow to ~30% of total revenue in FY 2027, doubling from 14%-15% in FY 2026, driven by new product launches, especially in Bolivia and other Latin American markets. - **B2B Segment**: Anticipated to grow at 25%-30% YoY, focusing on institutional and distributor-level sales. - **Geographical Expansion**: Increasing presence in over 40 countries; new markets include Myanmar, Nicaragua, Macedonia, Madagascar, with active filings in Peru, Asia-ASEAN, Middle East, Europe, and Africa.

2 more points from Remus Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Remus Pharmaceuticals is focused on an asset-light model, primarily outsourcing manufacturing to CMOs rather than investing heavily in fixed assets.
  • The company is creating infrastructure that may not be visibly asset-heavy but is critical from a brand-building perspective.
  • There have been investments in R&D (~Rs. 4 crores) including bioequivalence studies and clinical trials to access markets requiring human clinical data, enabling better margins.
  • The strategy is to continue without owning manufacturing assets, similar to models like Eris Pharmaceuticals before it acquired plants.
  • New subsidiaries, such as Espee Global Clinical Trial Services, are expected to become operational soon, which will contribute partially to margins.

2 more points from Remus Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
Some insights related to orders and business pipeline include: - The company holds inventory levels based on anticipated orders, especially in chronic therapy products, maintaining 4-6 months of stock to ensure uninterrupted supply. - The US and Latin American subsidiaries contribute significantly to working capital investment linked to inventory and distribution. - Product launches, such as 26 products planned for Bolivia in the next 2-3 months, indicate expanding order fulfillment. - The company is filing and preparing products, including Semaglutide and Pegfilgrastim PEG, for launches across multiple countries, some of which are awaiting patent expiries.

2 more points from Remus Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Remus Pharmaceuticals Ltd Q4 FY26 results?

Future Growth Expectations for Remus Pharmaceuticals: - Revenue Growth: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets. Remus Pharmaceuticals expects significant growth in both B2C and B2B segments in FY 2027.

What is Remus Pharmaceuticals Ltd share price analysis?

Remus Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 31.9 with a market cap of ₹1,181 Cr. Investors should review the full earnings analysis for detailed insights.

Is Remus Pharmaceuticals Ltd planning capital expenditure?

Remus Pharmaceuticals is focused on an asset-light model, primarily outsourcing manufacturing to CMOs rather than investing heavily in fixed assets.

Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.